木樨草素-7-二葡萄糖醛苷抗异丙肾上腺素诱导心肌损伤作用研究
|
摘要
目的:探索木樨草素-7-二葡萄糖醛酸苷(luteolin-7-diglucuronide,L7DG)通过口服干预,抗异丙肾上腺素(isoproterenol,ISO)所诱导心肌损伤的作用,为进一步临床应用提供有力的实验依据。方法:以10 mg·kg~(-1)的ISO持续腹腔注射5d,模拟C57BL/6雄性小鼠心肌损伤模型。于每次ISO腹腔注射前30 min分别给予L7DG两种剂量口服干预,即L7DG低剂量(120 mg·kg~(-1))与L7DG高剂量(240 mg·kg~(-1))。分别通过HE染色及Masson's染色,评价L7DG抗ISO所诱导的心肌损伤、心肌肥大以及纤维化的作用。结果:HE染色结果提示,与模型组相比,L7DG高剂量组与低剂量组炎性细胞浸润均显著降低(P <0. 05),此外,L7DG高剂量组与低剂量组均未见ISO诱导的左心室扩张性改变; Masson's染色结果提示,与模型组相比,L7DG高剂量组与低剂量组心肌纤维化沉积均显著降低(P <0. 05);与正常组相比,模型组左心室心肌横截面积显著增大(P <0. 05);而与模型组相比,L7DG高剂量组与低剂量组左心室心肌细胞横截面积均显著降低(P <0. 05)。结论:口服L7DG可显著减低ISO所诱导小鼠心肌损伤、纤维化、心肌细胞肥大的程度并改善左心室扩张性改变,这将为L7DG进一步应用于相关心血管疾病的治疗提供有力的临床支撑。
Objective: To explore the effect of Luteolin-7-diglucuronide( L7DG) on myocardial injury induced by isoproterenol( ISO) through oral intervention,and to provide a powerful experimental basis for further clinical application. Methods: The model of myocardial injury in C57BL/6 male mice was simulated by intraperitoneal injection of isoproterenol( 10 mg·kg~(-1)) for 5 days.Luteolin-7-diglucuronide was given orally at two doses 30 minutes before each intraperitoneal injection of isoproterenol,which is low doses of luteolin-7-diglucuronide( 120 mg·kg~(-1)) and high doses of luteolin-7-diglucuronide( 240 mg·kg~(-1)). HE staining and Masson's staining were used to evaluate the anti-isoproterenol-induced myocardial injury,hypertrophy and fibrosis effects of luteolin-7-diglucuronide. Results: HE staining results showed that compared with model group,luteolin-7-diglucuronide high-dose group and low-dose group significantly decreased inflammatory cell infiltration( P < 0. 05). In addition,no anti-isoproterenol-induced left ventricular dilatation was observed in the high-dose group and the low-dose group of luteolin-7-diglucuronide. Masson's staining results showed that compared with model group,luteolin-7-diglucuronide high-dose group and low-dose group significantly decreased myocardial fibrosis deposition( P < 0. 05). Compared with the normal group,the cross-sectional area of left ventricular myocardium in the model group increased significantly( P < 0. 05),while compared with the model group,the cross-sectional area of left ventricular myocardium in the high-dose luteolin-7-diglucuronide group and the low-dose group decreased significantly( P <0. 05). Conclusion: Oral administration of luteolin-7-diglucuronide can significantly reduce the degree of anti-isoproterenol-induced myocardial injury,fibrosis and cardiomyocyte hypertrophy in mice and improve left ventricular dilatation,which will provide strong clinical support for further application of luteolin-7-diglucuronide in the treatment of related cardiovascular diseases.
Objective: To explore the effect of Luteolin-7-diglucuronide( L7DG) on myocardial injury induced by isoproterenol( ISO) through oral intervention,and to provide a powerful experimental basis for further clinical application. Methods: The model of myocardial injury in C57BL/6 male mice was simulated by intraperitoneal injection of isoproterenol( 10 mg·kg~(-1)) for 5 days.Luteolin-7-diglucuronide was given orally at two doses 30 minutes before each intraperitoneal injection of isoproterenol,which is low doses of luteolin-7-diglucuronide( 120 mg·kg~(-1)) and high doses of luteolin-7-diglucuronide( 240 mg·kg~(-1)). HE staining and Masson's staining were used to evaluate the anti-isoproterenol-induced myocardial injury,hypertrophy and fibrosis effects of luteolin-7-diglucuronide. Results: HE staining results showed that compared with model group,luteolin-7-diglucuronide high-dose group and low-dose group significantly decreased inflammatory cell infiltration( P < 0. 05). In addition,no anti-isoproterenol-induced left ventricular dilatation was observed in the high-dose group and the low-dose group of luteolin-7-diglucuronide. Masson's staining results showed that compared with model group,luteolin-7-diglucuronide high-dose group and low-dose group significantly decreased myocardial fibrosis deposition( P < 0. 05). Compared with the normal group,the cross-sectional area of left ventricular myocardium in the model group increased significantly( P < 0. 05),while compared with the model group,the cross-sectional area of left ventricular myocardium in the high-dose luteolin-7-diglucuronide group and the low-dose group decreased significantly( P <0. 05). Conclusion: Oral administration of luteolin-7-diglucuronide can significantly reduce the degree of anti-isoproterenol-induced myocardial injury,fibrosis and cardiomyocyte hypertrophy in mice and improve left ventricular dilatation,which will provide strong clinical support for further application of luteolin-7-diglucuronide in the treatment of related cardiovascular diseases.
引文
[1]STANTON T,DUNN F G. Hypertension,left ventricular hypertrophy,and myocardial ischemia[J]. Med Clin North Am,2017,101(1):29-41.
[2]WONG T C,PIEHLER K,MEIER C G,et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality[J]. Circulation,2012,126:1206-1216.
[3]YIN Q,YANG C,WU J,et al. Downregulation ofβ-Adrenoceptors in isoproterenol-induced cardiac remodeling through HuR[J]. Plos One,2016,11(4):e0152005.
[4]BINGBING N,YONG Z,WU D D,et al. Luteolin-7-diglucuronide attenuates isoproterenol-induced myocardial injury and fibrosis in mice[J]. Acta Pharmacol Sin,2017,38(3):331-341.
[5]BERASHVILI D,ALANIYA M,BAKURIDZE A,et al. Luteolin diglucuronide from Perilla nankinensis[J]. Chemistry of Natural Compounds,2006,42(1):106-107.
[6]ZHANG S. Sudden cardiac death in China:current status and future perspectives[J]. Europace,2015,17(suppl 2):14-18.
[7]DEO R,ALBERT C M. Epidemiology and genetics of sudden cardiac death[J]. Circulation,2012,125(4):620-637.
[8]GLINGE C,SATTLER S,JABBARI R,et al. Epidemiology and genetics of ventricular fibrillation during acute myocardial infarction[J]. J Geriatr Cardiol,2016,13(9):789-797.
[9]AMBROSE J A,SINGH M. Pathophysiology of coronary artery disease leading to acute coronary syndromes[J]. Prime Rep,2015,7(1):14-18.
[10]PURNOMO Y,PICCART Y,COENEN T,et al. Oxidative stress and transforming growth factor-β1-induced cardiac fibrosis[J]. Cardiovasc Hematol Disord Drug Targets,2013,13(2):165-172.
[11]PRABHU S D,FRANGOGIANNIS N G. The biological basis for cardiac repair After myocardial infarction:from inflammation to fibrosis[J]. Circ Res,2016,119(1):91-112.
[12]肖冰冰,高东梅,冯海艳,等.扩张型心肌病患者左心室扭转与重构的关系[J].中华医学超声杂志(电子版),2016,13(6):430-432.
[13]MATSUI Y,MORIMOTO J,UEDE T. Role of matricellular proteins in cardiac tissue remodeling after myocardial infarction[J]. World J Biol Chem,2010,1(5):69-80.
[2]WONG T C,PIEHLER K,MEIER C G,et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality[J]. Circulation,2012,126:1206-1216.
[3]YIN Q,YANG C,WU J,et al. Downregulation ofβ-Adrenoceptors in isoproterenol-induced cardiac remodeling through HuR[J]. Plos One,2016,11(4):e0152005.
[4]BINGBING N,YONG Z,WU D D,et al. Luteolin-7-diglucuronide attenuates isoproterenol-induced myocardial injury and fibrosis in mice[J]. Acta Pharmacol Sin,2017,38(3):331-341.
[5]BERASHVILI D,ALANIYA M,BAKURIDZE A,et al. Luteolin diglucuronide from Perilla nankinensis[J]. Chemistry of Natural Compounds,2006,42(1):106-107.
[6]ZHANG S. Sudden cardiac death in China:current status and future perspectives[J]. Europace,2015,17(suppl 2):14-18.
[7]DEO R,ALBERT C M. Epidemiology and genetics of sudden cardiac death[J]. Circulation,2012,125(4):620-637.
[8]GLINGE C,SATTLER S,JABBARI R,et al. Epidemiology and genetics of ventricular fibrillation during acute myocardial infarction[J]. J Geriatr Cardiol,2016,13(9):789-797.
[9]AMBROSE J A,SINGH M. Pathophysiology of coronary artery disease leading to acute coronary syndromes[J]. Prime Rep,2015,7(1):14-18.
[10]PURNOMO Y,PICCART Y,COENEN T,et al. Oxidative stress and transforming growth factor-β1-induced cardiac fibrosis[J]. Cardiovasc Hematol Disord Drug Targets,2013,13(2):165-172.
[11]PRABHU S D,FRANGOGIANNIS N G. The biological basis for cardiac repair After myocardial infarction:from inflammation to fibrosis[J]. Circ Res,2016,119(1):91-112.
[12]肖冰冰,高东梅,冯海艳,等.扩张型心肌病患者左心室扭转与重构的关系[J].中华医学超声杂志(电子版),2016,13(6):430-432.
[13]MATSUI Y,MORIMOTO J,UEDE T. Role of matricellular proteins in cardiac tissue remodeling after myocardial infarction[J]. World J Biol Chem,2010,1(5):69-80.